enormous health, societal and economic burden associated with CKD demands that some priority should be given to the prevention and treatment of CKD in people with T2D. Sodium‐glucose co-transporter 2 (SGLT2) inhibitors have recently emerged as an
Page:12
SGLT2 inhibitors for patients with type 2 diabetes and CKD: a narrative review
Merlin C Thomas, Brendon L Neuen, Stephen M Twigg, Mark E Cooper, and Sunil V Badve
Improvement of skeletal muscle insulin sensitivity by 1 week of SGLT2 inhibitor use
Yuka Goto, Yoshie Otsuka, Kenji Ashida, Ayako Nagayama, Nao Hasuzawa, Shimpei Iwata, Kento Hara, Munehisa Tsuruta, Nobuhiko Wada, Seiichi Motomura, Yuji Tajiri, and Masatoshi Nomura
Introduction Sodium–glucose co-transporter 2 (SGLT2) inhibitors exert plasma glucose-lowering effects via urinary glucose excretion. Recent clinical trials have shown the various beneficial effects of SGLT2 inhibitors, including reductions in
Effects of SGLT2 inhibition on lipid transport in adipose tissue in type 2 diabetes
Katrine M Lauritsen, Jens Hohwü Voigt, Steen Bønløkke Pedersen, Troels K Hansen, Niels Møller, Niels Jessen, Lars C Gormsen, and Esben Søndergaard
Introduction Sodium-glucose cotransporter 2 (SGLT2) inhibitors are effective antidiabetic agents with remarkable cardiovascular benefits ( 1 ). Even though SGLT2 inhibitors primarily exert their pharmacological effect in the kidneys, the
Chronic kidney disease in patients with diabetes mellitus
Espen Nordheim and Trond Geir Jenssen
beneficial effects in patients with kidney disease beyond the blood-glucose lowering effect: receptor agonists of the glucagon-like protein 1 receptor (GLP-1 RA) and inhibitors of sodium-glucose-co-transporter-2 (SGLT2i). In secondary analyses of the SAVOR
Effect of COVID-19 on the clinical course of diabetic ketoacidosis (DKA) in people with type 1 and type 2 diabetes
Punith Kempegowda, Eka Melson, Agnes Johnson, Lucy Wallett, Lucretia Thomas, Dengyi Zhou, Catherine Holmes, Agata Juszczak, Mohammed Ali Karamat, Sandip Ghosh, Wasim Hanif, Parth Narendran, and Srikanth Bellary
negative (eight T1DM, three T2DM), and one pre-COVID (T2DM) had hypertension as a comorbidity. Six patients in COVID-positive and one person in COVID-negative group were on SGLT2 inhibitors; none of the people in the pre-COVID period were on this class of
The effects of empagliflozin vs metformin on endothelial microparticles in overweight/obese women with polycystic ovary syndrome
Zeeshan Javed, Maria Papageorgiou, Leigh A Madden, Alan S Rigby, Eric S Kilpatrick, Stephen L Atkin, and Thozhukat Sathyapalan
treatment with exenatide resulted in reductions in serum ICAM-1, p-selectin and e-selectin, although no pronounced changes were seen in endothelial function ( 25 ). Empagliflozin is a sodium-glucose cotransporter 2 (SGLT-2) inhibitor used in the treatment
Frequency and characteristics of diabetes in lipodystrophies and insulin receptoropathies compared with type 1 and type 2: results from the multicenter DPV registry
Clemens Kamrath, Alexander Eckert, Birgit Rami-Merhar, Sebastian Kummer, Martin Wabitsch, Katharina Laubner, Florian Kopp, Silvia Müther, Steffen Mühldorfer, and Reinhard W Holl
.0 4.0 4.8 ns ns 0.002 ns SGLT2 inhibitors 0.3 4.5 4.0 7.1 ns ns <0.001 ns Lipid-lowering drugs 6.9 28.3 28.0 19.1 0.001 ns ns ns Statins 6.4 26.4 8.0 16.7 ns ns ns ns
The functional duality of SGK1 in the regulation of hyperglycemia
Chunliang Yang, Junyi Li, Fei Sun, Haifeng Zhou, Jia Yang, and Chao Yang
enteral glucose absorption (alpha-glucosidase inhibitors) and increasing renal glucose excretion (SGLT-2 inhibitors). When mono-drug therapy fails, various combinations of drug administration are required for different clinical conditions. In worsened
Update on the impact of type 2 diabetes mellitus on bone metabolism and material properties
Ann-Kristin Picke, Graeme Campbell, Nicola Napoli, Lorenz C Hofbauer, and Martina Rauner
evidence is needed, GLP-1 agonists and dipeptidyl dipeptidase-4 inhibitors seem to have a safe bone health profile. Sodium-glucose cotransporter inhibitors These new generation drugs selectively inhibit the renal sodium-glucose cotransporter 2 (SGLT
Early and late endocrine complications of COVID-19
Paraskevi Kazakou, Stavroula A Paschou, Theodora Psaltopoulou, Maria Gavriatopoulou, Eleni Korompoki, Katerina Stefanaki, Fotini Kanouta, Georgia N Kassi, Meletios-Athanasios Dimopoulos, and Asimina Mitrakou
, irrespective of preexisting glycemic status, disease severity, or glucocorticoid use ( 49 , 50 ). Of note, several case series of euglycaemic DKA in patients with T2DM and COVID-19 while on sodium-glucose cotransporter-2 inhibitors (SGLT2is) have been
Page:12
